Genvec May Partner TNFerade
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II/III pancreatic cancer trial goes on, but firm may need help to push indications such esophageal cancer.
You may also be interested in...
The Sound Of Opportunity: Novartis Inks Deal With GenVec For Hearing Loss R&D
GenVec's gene-based program targets a hearing loss world ruled by devices.
The Sound Of Opportunity: Novartis Inks Deal With GenVec For Hearing Loss R&D
GenVec's gene-based program targets a hearing loss world ruled by devices.
GenVec Reports Positive Interim Survival Data For TNFerade In Pancreatic Cancer
Results presented at American Society of Clinical Oncology annual meeting show significant advantage in median survival versus standard care alone.